Pharmaceutical Innovations Inc is categorized under in Newark, NJ and active since 1971.
Pharmaceutical Innovations Inc was established in 1971, and today employs 1 to 4, earning $5.000.000 to $9.999.999 per year. This is a business, which does work in the BOTH market, and is classified as a , under code number 3254120 by the NAICS.
If you are seeking more information, feel free to contact Gilbert Buchalter, President at the company’s single location by writing to 897 Frelinghuysen Avenue, Newark, New Jersey NJ 07114 or by phoning (973) 242-2903. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Pharmaceutical Innovations Inc |
| Contact Person: | Gilbert Buchalter, President |
| Address: | 897 Frelinghuysen Avenue, Newark, New Jersey 07114 |
| Phone Number: | (973) 242-2903 |
| Website Address: | pharminnovations.com |
| Annual Revenue (USD): | $5.000.000 to $9.999.999 |
| Founded: | 1971 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B & B2C |
| Business Category: | |
| SIC Code: | 2834 |
| NAICS Code: | 3254120 |
| Share This Business: |
Pharmaceutical Innovations Inc was started in 1971 to provide professional under the SIC code 2834 and NAICS code 3254120. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $5.000.000 to $9.999.999 per annum.
Feel free to contact Gilbert Buchalter, President for inquiries that concern Pharmaceutical Innovations Inc by calling the company number (973) 242-2903, as your correspondence is most welcome. Additionally, the physical location of the single location of Pharmaceutical Innovations Inc can be found at the coordinates 40.69098,-74.20242 as well as the street address 897 Frelinghuysen Avenue in Newark, New Jersey 07114.
For its online presence, you may visit Pharmaceutical Innovations Inc’s website at pharminnovations.com and engage with its social media outlets through on Twitter and on Facebook.